Classifying Ectopia Lentis in Marfan Syndrome Into Five Grades of Increasing Severity

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT04319107
Collaborator
(none)
110
1
168
0.7

Study Details

Study Description

Brief Summary

Marfan syndrome is characterized by musculoskeletal manifestations, cardiovascular disease and ocular abnormalities, particularly ectopia lentis. Diagnosis depends on clinical evaluation, family history and molecular data: mutation in the fibrillin-1 gene (FBN1). Ectopia lentis is the most common ocular manifestation in Marfan syndrome with FBN1 mutation and is relatively specific to this disease when associated with other features. However, clinical examinations for identifying ectopia lentis have not really been codified. The purpose of this study is to describe a 5-grade classification of increasing severity for ectopia lentis based on clinical examination and to evaluate the predictive value for the early grades of ectopia lentis in order to help characterize this major clinical diagnosis criterion.

Condition or Disease Intervention/Treatment Phase
  • Other: ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.

Study Design

Study Type:
Observational
Actual Enrollment :
110 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Classifying Ectopia Lentis in Marfan Syndrome Into Five Grades of Increasing Severity
Actual Study Start Date :
Jan 1, 2000
Actual Primary Completion Date :
Dec 31, 2013
Actual Study Completion Date :
Dec 31, 2013

Arms and Interventions

Arm Intervention/Treatment
Marfan Syndrome (MFS) patients

Patients who had a clinical diagnosis of MFS according to the revised Ghent criteria (ectopia lentis was not taken into account for the diagnosis), confirmed by FBN1 sequencing.

Other: ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.
Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.

Control patients

Relatives of MFS patients with none of the clinical features of MFS and in whom testing for the familial FBN1 mutation was negative.

Other: ophthalmological examinations using a slit lamp bio microscopy and a three-mirror lens, standard procedure.
Pupillary dilatation was performed with instillation of tropicamide and phenylephrine. The ophthalmological examination included visual acuity measurement, using a slit lamp biomicroscopy to analyse the anterior segment and a three mirror lens to appreciate the quality of the dilation validated by the absence of pupillary reflex and to search for ectopia lentis. Ectopia Lentis grade is evaluated according to the 5-grade classification.

Outcome Measures

Primary Outcome Measures

  1. Ectopia lentis measurement [day 0]

    Ectopia lentis measurement and classification into 5-stages. Evaluation of the predictive value of ectopia lentis, at early stages, in order to help characterize this major clinical diagnosis criteria.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • MFS patient, clinical diagnosis according to revised Ghent criteria, confirmed by FBN1 mutation.

  • Relatives of MFS patients with none of the clinical features of MFS and in whom testing for the familial FBN1 mutation was negative.

Exclusion Criteria:
  • Patients who had surgery for ectopia lentis

  • Patients for whom dilation was not optimal.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hopital Femme Mère Enfant Bron France

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

  • Principal Investigator: Audrey Putoux, MD, Hospices Civils de Lyon

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT04319107
Other Study ID Numbers:
  • MARFAN_2020
First Posted:
Mar 24, 2020
Last Update Posted:
Mar 27, 2020
Last Verified:
Mar 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 27, 2020